Novo Nordisk said Thursday it will seek federal approval to expand the use of its Ozempic and Rybelsus pills to kids and ...

Novo Nordisk (NVO) on Thursday announced plans for a U.S. launch of the Ozempic pill, an oral version of its popular weight ...

Novo Nordisk (CPSE:NOVO B) reported strong phase 3 trial results for its oral semaglutide in children and adolescents with type 2 diabetes. The company plans to file for US and EU label expansions to ...

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...

Novo Nordisk NVO announced positive top-line results from the phase IIIa PIONEER TEENS study, evaluating oral semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), in children and ...

A late-stage trial showed that oral semaglutide significantly reduced blood sugar in 10- to 17-year-olds.

Armed with new phase 3 data, Novo Nordisk has said it will file for approval of oral formulations of its GLP-1 agonist ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Interest surrounding glucagon-like peptide 1 agonists (GLP-1), a class of type 2 diabetes drugs that help ...

This article reviews the main similarities and differences between Rybelsus and metformin. If you’re considering treatment with either drug, discussing this information with your doctor can help ...

Rybelsus (semaglutide) is a brand-name prescription medication that doctors prescribe alongside exercise and diet to help improve blood sugar levels in adults with type 2 diabetes. Plans often group ...

Rybelsus (semaglutide) is a brand-name oral tablet that’s prescribed for type 2 diabetes. The cost of the drug with and without insurance can depend on several factors, such as whether Rybelsus has a ...